SGMO
Sangamo Therapeutics Inc
NASDAQ: SGMO · HEALTHCARE · BIOTECHNOLOGY
$0.12
-10.24% today
Updated 2026-04-30
Market cap
$78.75M
P/E ratio
—
P/S ratio
1.99x
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$0 – $1
Volume
7.8M
Sangamo Therapeutics Inc (SGMO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-175.50%
ROE
-2,892.00%
ROA
-83.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $7.88M | $-17.86M | 100.00% | -262.89% | -226.56% |
| 2007 | $9.10M | $-21.48M | 100.00% | -272.27% | -236.10% |
| 2008 | $16.19M | $-24.30M | 100.00% | -156.77% | -150.14% |
| 2009 | $22.19M | $-18.59M | 100.00% | -87.45% | -83.77% |
| 2010 | $20.80M | $-24.85M | 100.00% | -119.85% | -119.46% |
| 2011 | $10.32M | $-35.75M | 100.00% | -347.14% | -346.45% |
| 2012 | $21.66M | $-22.26M | 100.00% | -102.51% | -102.81% |
| 2013 | $24.13M | $-26.62M | -53.23% | -110.66% | -110.32% |
| 2014 | $45.87M | $-26.42M | -23.71% | -58.38% | -57.59% |
| 2015 | $39.54M | $-40.70M | 100.00% | -118.51% | -102.94% |
| 2016 | $19.39M | $-71.66M | 100.00% | -374.23% | -369.58% |
| 2017 | $36.57M | $-54.57M | 100.00% | -154.13% | -149.23% |
| 2018 | $84.45M | $-68.33M | 100.00% | -91.35% | -80.91% |
| 2019 | $102.43M | $-75.82M | 100.00% | -102.69% | -74.02% |
| 2020 | $118.19M | $-121.12M | 100.00% | -109.61% | -102.48% |
| 2021 | $110.70M | $-178.30M | 100.00% | -165.61% | -161.06% |
| 2022 | $111.30M | $-192.28M | 100.00% | -180.85% | -172.76% |
| 2023 | $176.23M | $-257.83M | 100.00% | -155.48% | -146.30% |
| 2024 | $57.80M | $-97.94M | 100.00% | -179.88% | -169.45% |
| 2025 | $39.55M | $-122.93M | 80.78% | -273.07% | -310.81% |